Inovio Pharmaceuticals (MEX:INO) Institutional Ownership: 18.57% (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INO Inovio Pharmaceuticals Inc MEX:INO
40 GF Score
Price MXN11.50
GF Value MXN3.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Institutional Ownership?

Inovio Pharmaceuticals MEX:INO -36.11% 40 Institutional Ownership is 18.57% as of Jul. 31, 2026. GuruFocus rates MEX:INO with a GF Score™ of 40/100 and a GF Value™ of MXN3.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Inovio Pharmaceuticals's institutional ownership is 18.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Inovio Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Inovio Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 87.62%.

Inovio Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Institutional Ownership Chart

Inovio Pharmaceuticals Historical Data

The historical data trend for Inovio Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 9.59 9.59 23.21 23.18 23.16 23.29 22.27 17.82 18.26 18.57
MEX:INO
40GF Score
Inovio Pharmaceuticals Inc MEX:INO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 18.57% mean?
Inovio Pharmaceuticals (MEX:INO) has a Institutional Ownership of 18.57% as of Jul. 31, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Institutional Ownership too high?
Inovio Pharmaceuticals' current Institutional Ownership is 18.57%. Overall, Inovio Pharmaceuticals has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Institutional Ownership compare to TELO and ELTX?
Inovio Pharmaceuticals' Institutional Ownership of 18.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Institutional Ownership is 18.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (MEX:INO) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN3.68, compared to a current price of MXN11.50 — trading 212.5% above its estimated fair value. The current Institutional Ownership is 18.57%. Inovio Pharmaceuticals' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Inovio Pharmaceuticals (MEX:INO), the current Institutional Ownership is 18.57% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (MEX:INO) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of MXN11.50 is trading 212.5% above its estimated GF Value™ of MXN3.68. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEX:INO:

  • Institutional Ownership: 18.57%
  • GF Value™: MXN3.68 vs. price of MXN11.50 (212.5% above fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the MEX:INO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inovio Pharmaceuticals Business Description

Other Exchanges INO:USA0A43:UKGBM:Germany
Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
40GF Score

Get the complete analysis for MEX:INO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN11.50
Price
MXN3.68
GF Value